Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of 1,2,3,4-Tetrahydroisoquinoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.68 |
| ▸ | CD44 | P16070 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL6010101 | 0.89 | PNMT (0.79) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL4779021 | 0.87 | PNMT (0.76) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL16238882 | 0.86 | PNMT (0.63) | PNMTCD44MAOBHTR2CTSHR | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL6647088 | 0.85 | PNMT (0.73) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL4007316 | 0.85 | PNMT (0.73) | PNMTCD44MAOBHTR2CPRCP | |
| 4-Nitrobenzoic Acid SCHEMBL19029085 | 0.84 | PNMT (0.57) | PNMTCD44MAOBCES2CES1 | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL19085 | 0.82 | PNMT (1.00) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL29360217 | 0.82 | PNMT (1.00) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL28236302 | 0.82 | PNMT (1.00) | PNMTCD44MAOBHTR2CPRCP | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL11441365 | 0.82 | PNMT (0.68) | PNMTCD44MAOBHTR2CPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101668746-A | As histamine H3Tetrahydroisoquinoline compounds as receptor modulators | JANSSEN PHARMACEUTICA NV | 2010-03-10 | — | — | CN | disclosed |
| EP-2125741-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2009-12-02 | — | — | EP | disclosed |
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| WO-2008109336-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099158-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | PNMT 83/4885CD44 2071/4885MAOB 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.